Literature DB >> 19571821

The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population.

Elke Hacker1, Nicholas K Hayward, Troy Dumenil, Michael R James, David C Whiteman.   

Abstract

There is increasing epidemiological and molecular evidence that cutaneous melanomas arise through multiple causal pathways. The purpose of this study was to explore the relationship between germline and somatic mutations in a population-based series of melanoma patients to reshape and refine the divergent pathway model for melanoma. Melanomas collected from 123 Australian patients were analyzed for melanocortin-1 receptor (MC1R) variants and mutations in the BRAF and NRAS genes. Detailed phenotypic and sun exposure data were systematically collected from all patients. We found that BRAF-mutant melanomas were significantly more likely from younger patients and those with high nevus counts, and were more likely in melanomas with adjacent neval remnants. Conversely, BRAF-mutant melanomas were significantly less likely in people with high levels of lifetime sun exposure. We observed no association between germline MC1R status and somatic BRAF mutations in melanomas from this population. BRAF-mutant melanomas have different origins from other cutaneous melanomas. These data support the divergent pathways hypothesis for melanoma, which may require a reappraisal of targeted cancer prevention activities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19571821     DOI: 10.1038/jid.2009.182

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  28 in total

1.  The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.

Authors:  Elke Stadelmeyer; Ellen Heitzer; Margit Resel; Lorenzo Cerroni; Peter Wolf; Nadia Dandachi
Journal:  J Invest Dermatol       Date:  2013-08-09       Impact factor: 8.551

Review 2.  Biology and treatment of BRAF mutant metastatic melanoma.

Authors:  Benjamin Y Kong; Matteo S Carlino; Alexander M Menzies
Journal:  Melanoma Manag       Date:  2016-02-12

3.  Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.

Authors:  Nancy E Thomas; Sharon N Edmiston; Peter A Kanetsky; Klaus J Busam; Anne Kricker; Bruce K Armstrong; Anne E Cust; Hoda Anton-Culver; Stephen B Gruber; Li Luo; Irene Orlow; Anne S Reiner; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; Eloise A Parrish; Honglin Hao; David C Gibbs; Jill S Frank; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway
Journal:  J Invest Dermatol       Date:  2017-08-24       Impact factor: 8.551

4.  Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Authors:  Nancy E Thomas; Sharon N Edmiston; Audrey Alexander; Pamela A Groben; Eloise Parrish; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Lynn From; Klaus J Busam; Honglin Hao; Irene Orlow; Peter A Kanetsky; Li Luo; Anne S Reiner; Susan Paine; Jill S Frank; Jennifer I Bramson; Lorraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Anne E Cust; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

5.  Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.

Authors:  Shaowei Wu; Helen Kuo; Wen-Qing Li; Alvaro Laga Canales; Jiali Han; Abrar A Qureshi
Journal:  Cancer Causes Control       Date:  2014-07-22       Impact factor: 2.506

6.  Effect of hair color and sun sensitivity on nevus counts in white children in Colorado.

Authors:  Jenny Aalborg; Joseph G Morelli; Tim E Byers; Stefan T Mokrohisky; Lori A Crane
Journal:  J Am Acad Dermatol       Date:  2010-06-26       Impact factor: 11.527

7.  Dermoscopic features of cutaneous melanoma are associated with clinical characteristics of patients and tumours and with MC1R genotype.

Authors:  M C Fargnoli; F Sera; M Suppa; D Piccolo; M T Landi; A Chiarugi; C Pellegrini; S Seidenari; K Peris
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-03-04       Impact factor: 6.166

Review 8.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

9.  Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.

Authors:  Nancy E Thomas; Sharon N Edmiston; Irene Orlow; Peter A Kanetsky; Li Luo; David C Gibbs; Eloise A Parrish; Honglin Hao; Klaus J Busam; Bruce K Armstrong; Anne Kricker; Anne E Cust; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway
Journal:  J Invest Dermatol       Date:  2018-05-09       Impact factor: 8.551

Review 10.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.